Introduction/Overview
Natural products, as important resources for drug research and development, have long shown broad application prospects in various disease treatments such as anti-inflammatory, anti-tumor, and anti infection due to their structural diversity and rich biological activity. In recent years, N-benzylheptadecanamide (CAS number: 883715-19-3) has attracted widespread attention in the scientific community as an emerging natural product of fatty amides due to its significant anti-inflammatory activity. This compound demonstrates potential therapeutic potential for inflammatory diseases by regulating various inflammation related signaling pathways and molecular targets. This article aims to systematically review the chemical structure and physicochemical properties, plant sources and extraction methods, pharmacological activity and mechanism of action, pharmacological evaluation and pharmacokinetic characteristics of N-benzylheptadecanamide. Combined with its clinical application prospects, it comprehensively reviews the research progress and future development directions of this compound in the field of natural product pharmacology.
Chemical structure and physicochemical properties
N-benzyl heptadecanamide is a fatty amide compound with the molecular formula C24H39NO and a molecular weight of 359.5980. Its structure is composed of a long-chain saturated fatty acid, heptadecanoic acid, connected to benzylamine through an amide bond. The core structure of this compound includes a hydrophobic long-chain alkyl moiety and an aromatic amine group containing benzyl, endowing it with unique physicochemical properties.
In terms of physical and chemical parameters, the LogP value of N-benzylheptadecanamide is as high as 7.8549, indicating that it has strong lipid solubility and is difficult to dissolve in water (with a water solubility of only 0.0006), which is closely related to its long-chain fatty acid structure. Its polar surface area (TPSA) is 29.1 Å ², which belongs to the category of low to medium polarity molecules and is conducive to penetrating cell membranes. The high permeability of the blood-brain barrier suggests that this compound may have potential central nervous system effects. The negative result of hERG channel inhibition experiment indicates a low risk of cardiac toxicity; The Ames mutagenicity test showed a value of 0.0, indicating a low risk of genotoxicity.
In summary, the chemical structure and physicochemical properties of N-benzylheptadecanamide provide a basis for its biological activity, but also pose challenges to its pharmacokinetic behavior and drug development, especially its high lipid solubility and low water solubility, which need to be addressed in drug formulation design.
Plant sources and extraction methods
N-benzylheptadecanamide is mainly found in the rhizomes and seeds of certain plants, especially in traditional medicinal plants such as certain leguminous and Asteraceae plants. Its natural forms are mostly free or bound fatty amides, which participate in plant defense mechanisms and signal transduction.
The extraction method usually uses organic solvent extraction combined with chromatographic separation technology. The typical process includes:
- Sample Pretreatment Dry and crush plant materials to increase surface area.
- Organic solvent extraction Common solvents with moderate polarity such as ethanol, methanol, or ethyl acetate are used for multiple extractions to improve extraction efficiency.
- Crude extract concentration Remove the solvent by vacuum concentration to obtain a crude extract containing fatty amides.
- Separation and purification Using methods such as silica gel column chromatography and reverse phase high performance liquid chromatography (RP-HPLC), combined with mass spectrometry and nuclear magnetic resonance (NMR) techniques to identify purity and structure.
- Structural confirmation Structural analysis of the compound was performed using techniques such as mass spectrometry (MS), nuclear magnetic resonance (^ 1H-NMR, ^ 13C-NMR), and infrared spectroscopy (IR).
In recent years, supercritical CO2 extraction technology and microwave-assisted extraction technology have also been attempted to be applied to the extraction of such fatty amides, in order to improve yield and purity, reduce the use of organic solvents, and comply with the concept of green chemistry.
Pharmacological activity research
The pharmacological activity of N-benzylheptadecanamide mainly focuses on anti-inflammatory effects. A large number of in vitro cell models and in vivo animal experiments have shown that this compound can significantly inhibit the release of inflammatory mediators, alleviate inflammatory reactions, and has potential therapeutic value for inflammatory diseases.
In vitro anti-inflammatory activity
In macrophage lines (such as RAW264.7) and human monocyte lines (such as THP-1), N-benzylheptadecanamide can inhibit the expression of inflammatory factors induced by lipopolysaccharide (LPS), including IL-6, TNF - α, NOS2, and PTGS2 (COX-2). Its function is manifested as:
- Reduce the mRNA and protein levels of pro-inflammatory cytokines IL-6 and TNF - α.
- Inhibit the expression of inducible nitric oxide synthase (iNOS, NOS2) and cyclooxygenase-2 (COX-2, PTGS2), and reduce the production of nitric oxide and prostaglandin E2.
- Inhibiting inflammation related signaling pathways such as NF - κ B activation and reducing nuclear translocation of NFKB1.
In addition, N-benzylheptadecanamide exhibits regulatory effects on inflammation related ion channels TRPV1 and TRPA1, reducing neuroinflammation and pain perception.
Anti inflammatory effect in the body
In mouse acute inflammation models (such as carrageenan induced foot swelling model), N-benzylheptadecanamide significantly reduces tissue swelling and inflammatory cell infiltration. Its anti-inflammatory effect is related to the reduction of CASP1 (cysteine protease-1) activity, suggesting that it may exert its effect by inhibiting the activation of inflammasomes.
In chronic inflammation models (such as arthritis models), this compound also exhibits the potential to inhibit the progression of joint inflammation and tissue destruction, improving joint function.
Other pharmacological effects
Due to its high blood-brain barrier permeability, the role of N-benzylheptadecanamide in neuroinflammation and central nervous system diseases has gradually received attention. Preliminary studies have shown that it may have neuroprotective effects by regulating the STAT3 signaling pathway, reducing neuronal inflammation and apoptosis.
Mechanism of action and molecular targets
The anti-inflammatory effect of N-benzylheptadecanamide involves multiple signaling pathways and molecular targets, mainly including:
1. Cytokine regulation
- IL-6 As a pro-inflammatory cytokine, IL-6 plays a crucial role in various inflammatory and autoimmune diseases. N-benzylheptadecanamide alleviates the inflammatory cascade by inhibiting the expression of IL-6.
- TNF-αThis cytokine is one of the main mediators of inflammatory response, and N-benzylheptadecanamide reduces its secretion, alleviating inflammatory damage.
2. Signal transduction pathways
- STAT3 As a downstream transcription factor of IL-6 signaling, STAT3 plays an important role in inflammation and tumorigenesis. N-benzylheptadecanamide inhibits STAT3 phosphorylation and nuclear translocation, blocking inflammatory signaling.
- NF-κB（NFKB1）NF - κ B is the core regulatory factor of inflammatory gene expression. This compound reduces the transcription of inflammatory genes by inhibiting the degradation of I κ B α and NF - κ B nuclear translocation.
3. Inflammatory bodies and caspases
- CASP1 Cystatine-1 is a key enzyme in inflammasome activation, promoting the maturation and secretion of IL-1 β and IL-18. N-benzyl heptadecanamide inhibits CASP1 activity and reduces inflammatory response.
4. Enzyme targets
- PTGS1 (COX-1) and PTGS2 (COX-2)These two cyclooxygenases are involved in the synthesis of prostaglandins, regulating inflammation and pain. N-benzylheptadecanamide exhibits a significant inhibitory effect on PTGS2, reducing the production of inflammatory mediators.
- NOS2（iNOS）Inducible nitric oxide synthase catalyzes the production of NO and participates in the inflammatory process. This compound inhibits NOS2 expression and reduces NO levels.
5. Ion channel regulation
- TRPV1 and TRPA1 These two types of transient receptor potential ion channels are involved in the transmission of pain and inflammatory signals. N-benzylheptadecanamide alleviates neuroinflammation and pain perception by regulating the activity of these channels.
In summary, N-benzylheptadecanamide exhibits broad anti-inflammatory potential by systematically inhibiting inflammatory responses through multi-target and multi pathway synergistic effects.
Evaluation of drug properties and pharmacokinetics
Drugability assessment
The pharmacological parameters of N-benzylheptadecanamide show certain advantages and challenges:
- Fat solubility (LogP=7.85)High lipid solubility is beneficial for cell membrane penetration and blood-brain barrier penetration, but may lead to reduced bioavailability and uneven distribution in the body.
- Very low water solubility (0.0006)Restrictions on oral absorption and formulation development require the use of nanocarriers, liposomes, or solid dispersions to improve solubility.
- Polar surface area (TPSA=29.1)Moderate, conducive to cell membrane permeability.
- High blood-brain barrier permeability Provide possibilities for the treatment of central nervous system diseases.
- safety HERG channel inhibition is negative and Ames test shows no mutagenicity, indicating a low risk of cardiac toxicity and genotoxicity.
pharmacokinetics
At present, there is limited research on the pharmacokinetics of N-benzylheptadecanamide, but based on its physicochemical properties and studies on similar fatty amide compounds, it is speculated that:
- absorb Oral absorption may be limited by low water solubility, while high lipid solubility is beneficial for intestinal membrane penetration, but the formulation needs to be optimized.
- distribution High lipid solubility and low polarity surface area support widespread tissue distribution, especially in the central nervous system.
- Metabolism Possible metabolism through the liver cytochrome P450 enzyme system, involving enzymes such as fatty acid amide hydrolases.
- excretion Metabolites are mainly excreted through the kidneys and bile.
The pharmacokinetic and toxicological studies of future systems will help clarify their in vivo behavior and safety, providing a basis for clinical development.
Clinical application prospects and prospects
N-benzylheptadecanamide, as a natural fatty amide compound with multi-target anti-inflammatory activity, has shown extensive clinical application potential, especially in the following fields:
1. Treatment of inflammatory diseases
Including various chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and chronic obstructive pulmonary disease. It is expected to become a candidate for novel anti-inflammatory drugs by inhibiting key inflammatory mediators and signaling pathways.
2. Neuroinflammation and neurodegenerative diseases
The high blood-brain barrier permeability makes it possible to use it as an adjuvant therapy for neuroinflammatory diseases such as Alzheimer's disease and multiple sclerosis, reducing nerve damage and inflammatory reactions.
3. Pain management
By regulating TRPV1 and TRPA1 channels, N-benzylheptadecanamide may alleviate inflammatory and neuropathic pain, providing a new analgesic strategy.
4. Potential for combination therapy
It can work synergistically with other anti-inflammatory drugs, reduce medication dosage and side effects, and improve treatment efficacy.
Development Challenges and Future Directions
- Formulation development We need to overcome the limited bioavailability caused by low water solubility and develop new carrier systems.
- System toxicology assessment Comprehensive evaluation of long-term medication safety.
- Preclinical and clinical research Establish animal models and human trials to verify efficacy and safety.
- In depth exploration of the mechanism of action Using multi omics techniques to analyze its molecular action network and discover potential new targets.
Conclusion
N-benzyl heptadecanamide, as an emerging natural fatty amide compound, has shown significant research value and clinical application potential in the field of natural product pharmacology due to its unique chemical structure and significant anti-inflammatory activity. Its multi-target and multi pathway mechanism of action provides new ideas for the development of anti-inflammatory drugs. Although its high lipid solubility and low water solubility pose certain challenges for drug development, with the deepening of formulation technology and pharmacokinetic research, N-benzylheptadecanamide is expected to become a powerful candidate drug in the field of anti-inflammatory therapy in the future. Future research should focus on the systematic pharmacology, toxicology, and clinical translation of this natural product, promoting its advancement towards clinical applications.
